|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblasto
|
5R01CA190121-02
|
$332,000
|
$109,560
|
VERHAAK, ROELAND
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia
|
5R21CA190028-02
|
$169,650
|
$169,650
|
BONETTO, ANDREA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiati
|
1R21CA194679-01
|
$204,772
|
$204,772
|
JAMIESON, CATRIONA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-02
|
$553,684
|
$276,842
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers
|
5R01CA184968-02
|
$509,161
|
$254,581
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
5R01CA184502-02
|
$642,667
|
$642,667
|
WEROHA, SARAVUT
|
MAYO CLINIC ROCHESTER
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-02
|
$405,890
|
$405,890
|
SHARPLESS, NORMAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
2U54CA156733-06
|
$1,002,966
|
$80,237
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
|
1R21CA179362-01A1
|
$168,563
|
$168,563
|
CUI, ZHENGRONG
|
UNIVERSITY OF TEXAS, AUSTIN
|
|
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors
|
5R42CA156930-03
|
$532,072
|
$532,072
|
JONES, BARRY
|
ARISAPH PHARMACEUTICALS, INC.
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
5R44CA159843-03
|
$740,587
|
$740,587
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
A Novel Agent with Dual Functions to Treat Head and Neck Cancer
|
5R21CA176032-02
|
$171,825
|
$171,825
|
TOBACK, FREDERICK
|
UNIVERSITY OF CHICAGO
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
1R01CA183984-01A1
|
$472,669
|
$236,335
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer
|
1R43CA189613-01A1
|
$224,879
|
$224,879
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, INC.
|
|
A novel strategy to overcome resistance in Temozolomide-Refractory Glioblastomas
|
1R21CA195149-01
|
$179,619
|
$179,619
|
HERGENROTHER, PAUL
|
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
|
|
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection
|
5R01CA183074-02
|
$335,113
|
$335,113
|
YUAN, ZHI-MIN
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
|
A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma
|
5R21CA186140-02
|
$326,206
|
$326,206
|
BUTOWSKI, NICHOLAS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural
|
1R01CA198076-01
|
$621,329
|
$621,329
|
PORTNOW, JANA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
1R01CA199137-01
|
$424,296
|
$140,018
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
A radiotherapeutic for breast cancer brain metastases
|
5R21CA187528-02
|
$168,563
|
$168,563
|
MAKALE, MILAN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
A randomized trial of topical menthol for chemotherapy induced neuropathy
|
5R03CA181909-02
|
$80,000
|
$80,000
|
HERSHMAN, DAWN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer
|
5R01CA164447-05
|
$409,191
|
$409,191
|
BROWN, KATHLYNN
|
SRI INTERNATIONAL
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
5R01CA168900-04
|
$332,000
|
$166,000
|
POWELL, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
|
5R01CA169519-03
|
$299,746
|
$299,746
|
SALVEMINI, DANIELA
|
SAINT LOUIS UNIVERSITY
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
5K08CA160660-05
|
$156,330
|
$78,165
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S1
|
$62,498
|
$4,375
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S2
|
$125,000
|
$8,750
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-39
|
$7,704,373
|
$539,306
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Activating Bax as a therapeutic strategy for lung cancer
|
5R01CA175003-03
|
$309,952
|
$309,952
|
LI, CHI
|
UNIVERSITY OF LOUISVILLE
|
|
Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas
|
5R21CA182020-02
|
$171,825
|
$85,913
|
WEBER, MICHAEL
|
UNIVERSITY OF VIRGINIA
|
|
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu
|
5U54CA190152-02
|
$699,896
|
$146,978
|
GOPAL, SATISH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Adult Brain Tumor Consortium (ABTC)
|
5UM1CA137443-07
|
$1,999,085
|
$1,999,085
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
Aerobic Training During or After Adjuvant Therapy: A Randomized Trial
|
5R01CA164751-04
|
$156,197
|
$78,099
|
JONES, LEE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Affective Consequences of Chemotherapy
|
1R01CA194924-01A1
|
$425,094
|
$425,094
|
DEVRIES, ANNE
|
OHIO STATE UNIVERSITY
|
|
AIDS Malignancy Consortium (AMC)
|
2UM1CA121947-09
|
$13,134,493
|
$13,134,493
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
ALL therapy and developing brains: MRI measures, genetic factors and cognition
|
5R01CA090246-10
|
$380,224
|
$380,224
|
REDDICK, WILBURN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer
|
5R01CA182832-02
|
$323,700
|
$323,700
|
MATEI, DANIELA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Angiogenesis-targeting therapy for glioblastoma
|
5R01CA129371-08
|
$575,734
|
$287,867
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Antagonizing the SET Oncoprotein
|
1R43CA195879-01
|
$225,000
|
$225,000
|
VITEK, MICHAEL
|
COGNOSCI, INC.
|
|
Anti-Migration Therapy for Prevention and Treatment of Breast Tumor
|
5R01CA160271-05
|
$319,877
|
$159,939
|
TANAKA, TAKEMI
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
Antibody-interferon fusion proteins for treatment of B-cell malignancies
|
5R01CA162964-05
|
$319,550
|
$159,775
|
MORRISON, SHERIE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Anticancer Drug Pharmacology in Very Young Children
|
5R01CA154619-04
|
$433,475
|
$433,475
|
STEWART, CLINTON
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Anticancer drug-induced BH3-only protein.Bak interactions
|
5R01CA166741-04
|
$321,459
|
$321,459
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
|
Antitumor Agents: Structure and Synthesis
|
2R01CA019033-37A1
|
$293,247
|
$293,247
|
SMITH, AMOS
|
UNIVERSITY OF PENNSYLVANIA
|
|
Apoptosome Regulation in Leukemia by Protein Phosphatase 5 Hypoacetylation
|
5F31CA174243-03
|
$33,296
|
$33,296
|
FOSS, KRISTEN
|
DUKE UNIVERSITY
|
|
Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
|
5R01CA170595-04
|
$528,881
|
$528,881
|
GATENBY, ROBERT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer
|
2R01CA135354-05
|
$380,000
|
$380,000
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S5
|
$1,917,600
|
$172,584
|
KRAFT, ANDREW
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S6
|
$50,000
|
$4,500
|
KRAFT, ANDREW
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S7
|
$124,932
|
$11,244
|
KRAFT, ANDREW
|
UNIVERSITY OF ARIZONA
|
Total relevant funding to Chemotherapy for this search: $267,914,843
|